TAKE HOME MESSAGE: The administration of phosphodiesterase 5 inhibitor commencing at the time of castration might preserve erectile function. OBJECTIVE: To determine if sildenafil citrate treatment could improve erectile function after castration. To determine if sildenafil citrate treatment reduces collagenisation and apoptosis in erectile tissue after castration. MATERIALS AND METHODS: In all, 60 Sprague-Dawley rats were studied; the rats were divided into the following groups: sham - no orchidectomy (S), control - orchidectomy only (O) and treatment - orchidectomy plus sildenafil treatment (V), with 10 rats per group. Erectile haemodynamics assessment was done at 7 days (S7, O7, V7) and at 28 days (S28, O28, V28) yielding a total of six ...
INTRODUCTION: Sildenafil citrate is a type 5 phosphodiesterase inhibitor, which has demonstrated exc...
Bilateral cavernous nerve injury results in up-regulation of ROCK signaling in the penis. This is li...
Introduction: Orally active phosphodiesterase type 5 inhibitors (PDE5i), used in the treatment of er...
Objective/Background: Erectile dysfunction, a male sexual dysfunction generally develops due to impa...
Background: Because androgen replacement therapy (ART) is not performed immediately after the onset ...
OBJECTIVE To examine the effect of pioglitazone on erectile function in a rat model of postprostatec...
Aim: To investigate the effect of icariin on erectile function and the expression of nitric oxide sy...
Introduction: There is no consensus on the best oral phosphodiesterase type 5 inhibitor (PDE5I) for ...
© 2022 American Society of Andrology and European Academy of AndrologyBackground: The main pathophys...
The commonly utilized phosphodiesterase type 5 inhibitors do not lead to satisfactory penile erectio...
International audienceBackground: Botulinum toxin A (BTX-A) has a variety of uses in medicine. Some ...
International audienceBackground: Botulinum toxin A (BTX-A) has a variety of uses in medicine. Some ...
International audienceBackground: Botulinum toxin A (BTX-A) has a variety of uses in medicine. Some ...
Introduction: The development of novel therapeutic options is imperative in patients with erectile d...
OBJECTIVES: To examine whether chronic treatment with a type 5 phosphodiesterase inhibitor (PDE5I) c...
INTRODUCTION: Sildenafil citrate is a type 5 phosphodiesterase inhibitor, which has demonstrated exc...
Bilateral cavernous nerve injury results in up-regulation of ROCK signaling in the penis. This is li...
Introduction: Orally active phosphodiesterase type 5 inhibitors (PDE5i), used in the treatment of er...
Objective/Background: Erectile dysfunction, a male sexual dysfunction generally develops due to impa...
Background: Because androgen replacement therapy (ART) is not performed immediately after the onset ...
OBJECTIVE To examine the effect of pioglitazone on erectile function in a rat model of postprostatec...
Aim: To investigate the effect of icariin on erectile function and the expression of nitric oxide sy...
Introduction: There is no consensus on the best oral phosphodiesterase type 5 inhibitor (PDE5I) for ...
© 2022 American Society of Andrology and European Academy of AndrologyBackground: The main pathophys...
The commonly utilized phosphodiesterase type 5 inhibitors do not lead to satisfactory penile erectio...
International audienceBackground: Botulinum toxin A (BTX-A) has a variety of uses in medicine. Some ...
International audienceBackground: Botulinum toxin A (BTX-A) has a variety of uses in medicine. Some ...
International audienceBackground: Botulinum toxin A (BTX-A) has a variety of uses in medicine. Some ...
Introduction: The development of novel therapeutic options is imperative in patients with erectile d...
OBJECTIVES: To examine whether chronic treatment with a type 5 phosphodiesterase inhibitor (PDE5I) c...
INTRODUCTION: Sildenafil citrate is a type 5 phosphodiesterase inhibitor, which has demonstrated exc...
Bilateral cavernous nerve injury results in up-regulation of ROCK signaling in the penis. This is li...
Introduction: Orally active phosphodiesterase type 5 inhibitors (PDE5i), used in the treatment of er...